DOMH
Get informed when a big investor buys or sells
+ FollowOvervalued by 7.3% based on the discounted cash flow analysis.
| Market cap | $59.60 Million |
|---|---|
| Enterprise Value | $55.04 Million |
| Dividend Yield | $0.96 (26.02%) |
| Earnings per Share | $-1.57 |
| Beta | 0.71 |
| Outstanding Shares | 18,068,269 |
| P/E Ratio | -1.41 |
|---|---|
| PEG | -1.85 |
| Price to Sales | 0.41 |
| Price to Book Ratio | 3.26 |
| Enterprise Value to Revenue | 0.36 |
| Enterprise Value to EBIT | 0.83 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.42 |
| Debt to Equity | 0.73 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 25,200▼ 69.57% |
| Total Puts | - |
Holdings and activity of institutional investors.
| Ownership % | 11.25%▲ 1.06% |
|---|---|
| Total Invested | $5.22M▼ 32.53% |
| Investors Holding | 31▼ 9.00% |
No data
AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company's platform consists of patented technology from leading universities and res...